Skip to main content
Log in

Komorbidität illegaler Drogen

Psychische und somatische Störungen durch Cannabiskonsum

  • Zertifizierte Fortbildung
  • Published:
DNP - Der Neurologe & Psychiater Aims and scope

Zusammenfassung

Etwa 5 % der Erwachsenenbevölkerung konsumieren Cannabinoide, aber nur 0,5 % weisen einen schädlichen oder abhängigen Konsum auf. Die Organtoxizität von Cannabis wird unterschätzt, die Hauptprobleme und Folgeschäden liegen aber im psychischen Bereich. Dazu zählen kognitive Störungen, amotivationales Syndrom, Psychosen und Wahnerkrankungen, affektive und Angsterkrankungen sowie Intoxikationen und die psychische und körperliche Abhängigkeit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Majic T, Kienast T, Heinz A, Soyka M. Drogen- und Medikamentenabhängigkeit. 2016 In: Möller HJ, Laux G, Kapfhammer H-P (Hrsf) Psychiatrie, Psychosomatik, Psychotherapie. Springer Reference Medizin 10.1007/978-3-642-45028_62-1

  2. United Nations Office on Drugs and Crime,World Drug Report 2016 (United Nations publication, Sales No. E.16.XI.7)

  3. Pabst A, Kraus L, Gomes de Matos E, Piontek D. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013; 59: 321–31

    Article  Google Scholar 

  4. Europäische Beobachtungsstelle für Drogen und Drogensucht (2016), Europäischer Drogenbericht 2016: Trends und Entwicklungen, Amt für Veröffentlichungen der Europäischen Union, Luxemburg.

  5. Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012; 109: 495–501.

    PubMed  PubMed Central  Google Scholar 

  6. Cascini F, Aiello C, Di Tanna G: Increasing delta-9-tetrahydrocannabinol (Delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32–40.

    Article  CAS  Google Scholar 

  7. Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2: 241–54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Niesink R, van Laar MW: Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry 2013; 4: 130.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS One 2013; 24: 8.

    Google Scholar 

  10. Behrendt S, Wittchen HU, Höfler M, Lieb R, Beesdo K (2009) Transitions from first use to substance use disorders in adolescence: is early onset associated with a rapid escalation? Drug Alcohol Depend 99: 68–78

  11. DBDD (2016), DEUTSCHLAND Bericht 2016 des nationalen REITOX-Knotenpunkts an die EBDD (Datenjahr 2015 / 2016) Behandlung, München: IFT Institut für Therapieforschung.

  12. (Piontek et al. 2016) Bundesministerium für Gesundheit (BMG). Drogen- und Suchtbericht 2015.

  13. Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int 2015; 112: 271–8.

    PubMed  PubMed Central  Google Scholar 

  14. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015; 110: 19–35

    Article  PubMed  Google Scholar 

  15. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effect of marijuana use. N Engl J Med. 2014; 370 (23): 2219–2227

    Article  PubMed  PubMed Central  Google Scholar 

  16. Bonnet U, Harries-Hedder K, Leweke FM, Schneider U, Tossmann P: AWMF-Leitlinie: Cannabis-bezogene Störungen. In: LG Schmidt, M Gastpar, P Falkai, W Gaebel (Hrsg.) Evidenzbasierte Suchtmedizin, Deutscher Ärzteverlag, Köln (2006) S. 143–170

  17. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004 Nov;161(11):1967–77

  18. Preuss UW, Hoch E, Schneider M, Bonnet U, Scherbaum N. Evidenzbasierte Behandlung der Cannabisabhängigkeit. In: Backmund M (ed.): Sucht-Therapie Grundlagen - Klinik - Standards - Leitfaden für Praxis und Fortbildung. 28. Ergänzung, 2016.

  19. Solowij, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008; 1: 81–98

    Article  PubMed  Google Scholar 

  20. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. Drug Test Anal 2014; 6: 39–45.

    Article  CAS  PubMed  Google Scholar 

  21. Grant I, Gonzales R, Caraey CL, Natarajan L, Wolfson T: Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9: 679–89.

    Article  CAS  PubMed  Google Scholar 

  22. Schreiner AM, Dunn ME: Residual effects of cannabis use on neurocognitive performance after prolong abstinence: a meta-analysis. Exp Clin Psychopharmacol 2012; 20:420–29

    Article  PubMed  Google Scholar 

  23. Medina KL, Hanson KL, Schweinsburg AD, et al: Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. J Int. Neuropsychol Soc 2007; 13: 807–20

    Article  PubMed  PubMed Central  Google Scholar 

  24. Solowij Nk, Jones KA, Rozman ME, et al: Verbal learning and memory in adoleslllcent cannabis users, alcohol users and non-users. Psychopharmacology 2011; 216: 131–44

    Article  CAS  PubMed  Google Scholar 

  25. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE et al (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA; 109: E2657–2664

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lisdahl KM, Gilbart ER, Wright NE, Shollenbarger S: Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry 2013; 4: 53

    Article  PubMed  PubMed Central  Google Scholar 

  27. Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N. Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biol Psychiatry. 2016;79(7): 557–67.

    Article  CAS  PubMed  Google Scholar 

  28. Kessler RC, Berglund P, Chiu WT, et al.: The US National Comor bidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res 2004; 13: 69–92.

    Article  PubMed  Google Scholar 

  29. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007; 64: 57–64.

    Article  PubMed  Google Scholar 

  30. Silberberg C, Castle D, Koethe D. Cannabis, cannabinoids, and bipolar disorder. In: Castle D, Murray R, D‘Souza D (eds.). Marijuana and madness. 2nd edition. Cambridge University Press. New York 2012; 129–36.

  31. Lev-Ran S, Le FB, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: Characteristics, comorbidities and clinical correlates. Psychiatry Res 2013; 209: 459–65.

    Article  PubMed  Google Scholar 

  32. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population—a meta-analysis of 31 studies. BMC Psychiatry. 2014;14: 136

    Article  PubMed  PubMed Central  Google Scholar 

  33. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–28.

    Article  PubMed  Google Scholar 

  34. Serafini G, Pompili M, Innamorati M, Temple EC, Amore M, Borgwardt S, Girardi P. The Association between Cannabis Use, Mental Illness, and Suicidal Behavior: What is the Role of Hopelessness? Front Psychiatry. 2013 11;4: 125.

    Google Scholar 

  35. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull. 2016;42(5): 1262–9

    Article  PubMed  Google Scholar 

  36. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011; 68(6): 555–61.

    Article  PubMed  Google Scholar 

  37. Myles N, Newall H, Compton MT, Curtis J, Nielssen O, Large M. The age at onset of psychosis and tobacco use: a systematic meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2012;47(8): 1243–50.

    Article  PubMed  Google Scholar 

  38. Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, Camuri G, Altarnura AC, Murray R, Bhattacharyya S. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 2016; 3:215–225.

    Article  PubMed  Google Scholar 

  39. Rawal SY, Tatakis DN, Tipton DA. Periodontal and oral manifestations of marijuana use. J Tenn Dent Assoc 2012; 92(2): 26–31

    PubMed  Google Scholar 

  40. Karila L, Roux P, Rolland B. Acute and long-term effects of cannabis use: A Review. Curr Pharm 2014; 20: 4112–8.

    Article  CAS  Google Scholar 

  41. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42(1): 63–71.

    Google Scholar 

  42. Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011; 4: 241–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Gessford AK, John M, Nicholson B, Trout R. Marijuana induced hyperemesis: a case report. W V Med J. 2012; 108(6):20–22.

    PubMed  Google Scholar 

  44. Tetrault J, Crothers K, Moore B, Mehra R, Concato J, Fiellin D. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167: 221–8.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Owen KP, Sutter ME, Albertson TE: Marijuana: respiratory tract effects. Clin Rev Allergy Immunol 2014; 46: 65–81.

    Article  CAS  PubMed  Google Scholar 

  46. Tessmer A, Berlin N, Sussman G, Leader N, Chung EC, Beezhold D. Hypersensitivity reactions to marijuana. Ann Allergy Asthma Immunol 2012; 108: 282–4

    Article  PubMed  Google Scholar 

  47. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990 Mar; 87(5):1932–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A et al. Effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007; 62: 1058–63.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Callaghan R C, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 2013; 24: 1811–20.

    Article  PubMed  Google Scholar 

  50. Pratap B, Korniyenko A. Toxic effects of marijuana on the cardiovascular system. Cardiovasc Toxicol 2012; 12: 143–8.

    Article  PubMed  Google Scholar 

  51. Bachs L, Morland H: Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124: 200–3.

    Article  CAS  PubMed  Google Scholar 

  52. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103: 2805–9.

    Article  CAS  PubMed  Google Scholar 

  53. Hartung B, Kauferstein S, Ritz-Timme S, Daldrup T Sudden unexpected death under acute influence of cannabis. Forensic Sci Int. 2014; 237:e11–3

    Article  PubMed  Google Scholar 

  54. Mukamal KJ, Maclure M, Muller JE, Mittleman MA. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J 2008; 155: 465–70.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Jouanjus E., Leymarie F., Tubery M., Lapeyre-Mestre M. Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Br J Clin Pharmacol 2011; 71: 758–65

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res 2012; 71: 215–9.

    Article  PubMed  Google Scholar 

  57. Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol 2011; 6(4): 459–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Bari M, Battista N, Pirazzi V, Maccarrone M. The manifold actions of endocannabinoids on female and male reproductive events. Front Biosci 2011; 16: 498–516.

    Article  CAS  Google Scholar 

  59. Feng BJ, Khyatti M, Ben-Ayoub W, et al.: Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer 2009; 101: 1207–12.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Berthiller J, Straif K, Boniol M, et al. Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 2008; 3: 1398–403.

    Article  PubMed  Google Scholar 

  61. Moir D, Rickert W, Levasseur G, Larose Y, Maertens R, White P et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008; 21: 494–502.

    Article  CAS  PubMed  Google Scholar 

  62. Callaghan R C, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 2013; 24: 1811–20.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ulrich W. Preuss.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. E. Hoch erklärt den Erhalt von Honoraren für ein Therapiemanual des Hofgrefe-Verlags sowie für Vorträge und Weiterbildungen zum Thema „Cannabis“ an Klinken.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Preuss, U.W., Hoch, E. Psychische und somatische Störungen durch Cannabiskonsum. DNP 18, 45–54 (2017). https://doi.org/10.1007/s15202-017-1499-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-017-1499-8

Navigation